// App-Quantinova.ai

e17092 : Toxicity related to first line, platinum-based chemotherapy in BRCA1-associated epithelial ovarian cancer: Is DNA repairing impairment associated with more adverse events?

Researchers

Presenter

  • Agnieszka Badora-Rybicka

Principal Investigators

  • Magdalena Budryk

  • Danuta Starzyczny-Sota

  • Elzbieta Nowara

Medical Centers

  • Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Gliwice Branch, Gliwice, Poland

  • Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Gliwice Branch, Gliwice, Poland

  • Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Gliwice Branch, Gliwice, Poland

  • Clinical and Experimental Oncology Department, Maria Sklodowska Curie Memorial Cancer Centere and Institue of Oncology (COI), Gliwice Branch, Gliwice, Poland

Locations

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Ovarian cancer

  • Peripheral neuropathy

  • Mucositis

  • Solid malignancies

Biomarkers

  • BRCA mutation

Drug/Treatment

  • Paclitaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved